Trial Outcomes & Findings for Mobile Contingency Management for Marijuana and Tobacco Cessation (NCT NCT02869451)

Results Overview

Participants self-report smoking behavior since smoking quit date. Prolonged abstinence is defined as sustained abstinence since two weeks post-initial smoking quit date.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

7 participants

Primary outcome timeframe

6 month follow up

Results posted on

2020-02-07

Participant Flow

Study recruitment occurred between August 2016 to May 2017. Participants were recruited from community settings and Craigslist.

Seven participants signed consent. Two of these participants were withdrawn by the principal investigator after signing consent because they did not meet study eligibility criteria.

Participant milestones

Participant milestones
Measure	Treatment Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Overall Study STARTED	5
Overall Study COMPLETED	5
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Mobile Contingency Management for Marijuana and Tobacco Cessation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Age, Continuous	43.6 years STANDARD_DEVIATION 8.87 • n=5 Participants
Sex: Female, Male Female	4 Participants n=5 Participants
Sex: Female, Male Male	1 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	4 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	5 Participants n=5 Participants
Race (NIH/OMB) White	0 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Region of Enrollment United States	5 participants n=5 Participants

PRIMARY outcome

Timeframe: 6 month follow up

Participants self-report smoking behavior since smoking quit date. Prolonged abstinence is defined as sustained abstinence since two weeks post-initial smoking quit date.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Self-report Prolonged Abstinence From Smoking	0 Participants

PRIMARY outcome

Timeframe: 6 month follow up

Self-reported abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Report Smoking Abstinence and Abstinence is Bioverified by Salivary Cotinine	0 Participants

PRIMARY outcome

Timeframe: 6 month follow up

Participants self-report marijuana use since marijuana quit date. Prolonged abstinence is defined as sustained abstinence since two weeks post-initial quit date.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Self-report Prolonged Abstinence From Marijuana Use	0 Participants

PRIMARY outcome

Timeframe: 6 month follow up

Self-reported abstinence (primary outcome) will be verified by oral fluid (OF) cannabis assessment. Oral fluid samples will be collected from participants who self-report prolonged abstinence.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Report Marijuana Abstinence and Abstinence is Bioverified by Oral Fluid	0 Participants

SECONDARY outcome

Timeframe: 6 month follow up

7-day point prevalence abstinence is defined as no smoking in the prior 7 days.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking	1 Participants

SECONDARY outcome

Timeframe: 6 month follow up

7-day point prevalence abstinence is defined as no marijuana use in the prior 7 days.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Marijuana	2 Participants

SECONDARY outcome

Timeframe: 6 month follow up

30-day point prevalence abstinence is defined as no marijuana use in the prior 30 days.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Report 30 Day Point Prevalence Abstinence From Marijuana	1 Participants

SECONDARY outcome

Timeframe: 6 month follow up

30-day point prevalence abstinence is defined as no smoking in the prior 30 days.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking	1 Participants

SECONDARY outcome

Timeframe: 3 month follow up

7-day point prevalence abstinence is defined as no smoking in the prior 7 days.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Report 7 Day Point Prevalence Abstinence From Smoking	0 Participants

SECONDARY outcome

Timeframe: 3 month follow up

7-day point prevalence abstinence is defined as no marijuana use in the prior 7 days.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Report 7 Day Point Prevalence Abstinence From Marijuana	3 Participants

SECONDARY outcome

Timeframe: 3 month follow up

Self-reported abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Report Smoking Abstinence and Abstinence is Bioverified by Salivary Cotinine	0 Participants

SECONDARY outcome

Timeframe: 3 month follow up

Self-reported abstinence (primary outcome) will be verified by oral fluid (OF) cannabis assessment. Oral fluid samples will be collected from participants who self-report prolonged abstinence.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Participants Who Report Marijuana Abstinence and Abstinence is Bioverified by Salivary Cotinine	3 Participants

SECONDARY outcome

Timeframe: baseline, 6 month follow up

Participants will self-report amount of marijuana used in past week; this will be compared to self-reported amount smoked per week prior to quit date.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Change From Baseline in Number of Days Per Week of Cannabis Use	-3.4 days per week of marijuana use Standard Deviation 1.34

SECONDARY outcome

Timeframe: 30 days prior to quit date, 6 month follow up

Participants will self-report number of days marijuana used in the past 30 days and this will be compared for the entire group to self-reported number of days of use in 30 days prior to quit. The proportion will be calculated by totaling baseline days used and pretreatment days used, and then dividing baseline days used by pretreatment days used.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Proportional Change in Days of Cannabis Use From Pre-quit to 6 Month Follow-up (Entire Group)	28 percentage of pre-quit use

SECONDARY outcome

Timeframe: 7 days prior to quit date, 6 month follow up

Self-reported number of cigarettes smoked each day in past 7 days; this will be compared to self-reported amount smoked in week prior to quit date

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Change in Number of Cigarettes Smoked Per Week Compared to Pre-quit	-37.8 number of cigarettes per wk Standard Deviation 39.16

SECONDARY outcome

Timeframe: 30 days prior to quit date, 6 month follow up

Participants will self-report number of days smoked in the past 30 days and this will be compared (for the entire group) to self-reported number of days smoked in 30 days prior to quit. The proportion will be calculated by totaling baseline days used and pretreatment days used, and then dividing baseline days used by pretreatment days used.

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Proportional Change in Days Smoked From Pre-quit to 6-month Follow up (for Entire Group)	80 percentage of pre-quit use

SECONDARY outcome

Timeframe: 3 month follow up

Participants upload video recordings of abstinence verification as part of contingency management treatment. Percentage of missed videos (compared to expected videos) will be assessed as a measure of feasibility of the contingency management intervention

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Percentage of Missing Mobile Contingency Management Video Recordings	33.9 percent missed video recordings

SECONDARY outcome

Timeframe: 3 month follow up

Participants attend telephone counseling sessions. Number of missed sessions for the total group will be assessed as a measure of acceptability of the behavioral counseling

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Missed Behavioral Counseling Sessions	0 missed counseling sessions

SECONDARY outcome

Timeframe: Evaluated at 6 month follow-up

The number of participants who withdraw from the study will be evaluated as a measure of treatment feasibility and acceptability

Outcome measures

Outcome measures
Measure	Treatment n=5 Participants Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Number of Voluntary Withdrawals From the Project	0 Participants

Adverse Events

Treatment

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Treatment n=5 participants at risk Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months. bupropion: Prescribed one week prior to quit and continued until the 6 month follow-up visit. transdermal nicotine patch: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant Nicotine polacrilex: Initiated at smoking quit date. nicotine lozenge: Initiated at smoking quit date. counseling for marijuana and smoking cessation: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention mobile contingency management: treatment that provides money rewards for abstinence from smoking and marijuana
Gastrointestinal disorders Nausea with bupropion use	20.0% 1/5 • Number of events 1 • Adverse events were collected for approximately seven months, from informed consent signature to 6-month follow-up (which occurred 6 months after substance cessation date).

Additional Information

Angela Kirby

Duke University Medical Center

Phone: 919-286-0411

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place